Cost-Effectiveness of HIV Treatment as Prevention in Serodiscordant Couples
Authors:
- Rochelle P. WalenskyRWRochelle P. Walensky
- Eric L. RossEREric L. Ross
- Nagalingeswaran KumarasamyNKNagalingeswaran Kumarasamy
- Robin WoodRWRobin Wood
- Farzad NoubaryFNFarzad Noubary
- A. David PaltielAPA. David Paltiel
- Yoriko M. NakamuraYNYoriko M. Nakamura
- Sheela V. GodboleSGSheela V. Godbole
- Ravindre PanchiaRPRavindre Panchia
- Ian SanneISIan Sanne
- Milton C. WeinsteinMWMilton C. Weinstein
- Elena LosinaELElena Losina
Open Access
- 31 October 2013
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 369 (18) , 1715-1725
Abstract
The cost-effectiveness of early antiretroviral therapy (ART) in persons infected with human immunodeficiency virus (HIV) in serodiscordant couples is not known. Using a computer simulation of the progression of HIV infection and data from the HIV Prevention Trials Network 052 study, we projected the cost-effectiveness of early ART for such persons. For HIV-infected partners in serodiscordant couples in South Africa and India, we compared the early initiation of ART with delayed ART. Five-year and lifetime outcomes included cumulative HIV transmissions, life-years, costs, and cost-effectiveness. We classified early ART as very cost-effective if its incremental cost-effectiveness ratio was less than the annual per capita gross domestic product (GDP; $8,100 in South Africa and $1,500 in India), as cost-effective if the ratio was less than three times the GDP, and as cost-saving if it resulted in a decrease in total costs and an increase in life-years, as compared with delayed ART. In South Africa, early ART prevented opportunistic diseases and was cost-saving over a 5-year period; over a lifetime, it was very cost-effective ($590 per life-year saved). In India, early ART was cost-effective ($1,800 per life-year saved) over a 5-year period and very cost-effective ($530 per life-year saved) over a lifetime. In both countries, early ART prevented HIV transmission over short periods, but longer survival attenuated this effect; the main driver of life-years saved was a clinical benefit for treated patients. Early ART remained very cost-effective over a lifetime under most modeled assumptions in the two countries. In South Africa, early ART was cost-saving over a 5-year period. In both South Africa and India, early ART was projected to be very cost-effective over a lifetime. With individual, public health, and economic benefits, there is a compelling case for early ART for serodiscordant couples in resource-limited settings. (Funded by the National Institute of Allergy and Infectious Diseases and others.)Keywords
This publication has 29 references indexed in Scilit:
- Analysis of Genetic Linkage of HIV From Couples Enrolled in the HIV Prevention Trials Network 052 TrialThe Journal of Infectious Diseases, 2011
- Timing of HAART Initiation and Clinical Outcomes in Human Immunodeficiency Virus Type 1 SeroconvertersArchives of internal medicine (1960), 2011
- Prevention of HIV-1 Infection with Early Antiretroviral TherapyNew England Journal of Medicine, 2011
- The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling studyThe Lancet, 2011
- Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysisThe Lancet, 2010
- Patient retention in antiretroviral therapy programs up to three years on treatment in sub‐Saharan Africa, 2007–2009: systematic reviewTropical Medicine & International Health, 2010
- Antiretroviral Therapy Adherence, Virologic and Immunologic Outcomes in Adolescents Compared With Adults in Southern AfricaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Effect of Early versus Deferred Antiretroviral Therapy for HIV on SurvivalNew England Journal of Medicine, 2009
- Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical modelThe Lancet, 2009
- Scaling Up Antiretroviral Therapy in South Africa: The Impact of Speed on SurvivalThe Journal of Infectious Diseases, 2008